|
| Press Releases |
|
 |
|
| Thursday, August 4, 2022 |
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 |
| Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype. more info >> |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Melbourne's Deputy Lord Mayor shares city's path forward at PropertyGuru Asia Property Awards (Australia) launch
Apr 29, 2025 23:58 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Delivers Record $2.5 Billion in Retail Sales for 2024, Targets $3 Billion and 1,500 U.S. Polo Assn. Stores
Apr 29, 2025 22:48 HKT/SGT
|
|
|
The Apipatana Foundation Donates S$50,000 to Support Lower-Income Students in Singapore
Apr 29, 2025 22:47 HKT/SGT
|
|
|
HydroFleet Propels Hydrogen Revolution Forward With HTWO Logistics Collaboration in Savannah, GA
Apr 29, 2025 22:47 HKT/SGT
|
|
|
DataBurning and Vumonic Announce Strategic Partnership for India E-Receipt Data
Apr 29, 2025 22:46 HKT/SGT
|
|
|
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 29, 2025 22:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
|
|
|
Open Dialogue 'Future of the World. New Platform for Global Growth' Launches at Russia National Centre 
Apr 29, 2025 15:00 HKT/SGT
|
|
|
HKTDC's April lifestyle fairs open today
Apr 29, 2025 12:42 HKT/SGT
|
|
|
Azurite Medical and Wellness Launches Revolutionary Luxury Surgical Retreat Concept in Global Medical Tourism Market
Apr 29, 2025 02:09 HKT/SGT
|
|
|
Hong Kong International Licensing Show and Asian Licensing Conference Open Today
Apr 28, 2025 22:46 HKT/SGT
|
|
|
Hung Fook Tong Partners with Nutribite to Launch AI-Powered Personalised Healthy Meal Service
Apr 28, 2025 15:51 HKT/SGT
|
|
|
Q2 Metals Extends Mineralized Zone Strike Length to 1.5 Kilometres and Concludes the 2025 Winter Program at the Cisco Lithium Project in Quebec, Canada
Apr 28, 2025 15:05 HKT/SGT
|
|
|
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1Q2025 Results
Apr 28, 2025 11:25 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
